Evolution of OGTT in patients with β-thalassaemia major in relation to chelation therapy

Diabetes Research and Clinical Practice

Volumn 76, Issue 1, 2007, Pages 6-11

  Christoforidis, Athanasios ^a   Perifanis, Vassilios ^a   Tsatra, Ioanna ^a   Vlachaki, Efthimia ^a   Athanassiou Metaxa, Miranda ^a  

^a Aristotle University of Thessaloniki   (Greece)

Author keywords

thalassaemia major; Combined treatment; Deferiprone; Deferoxamine; Glucose disturbances; OGTT

Indexed keywords

ANTIDIABETIC AGENT; DEFERIPRONE; DEFEROXAMINE;

ADOLESCENT; ADULT; ARTICLE; BETA THALASSEMIA; CELL FUNCTION; CHELATION THERAPY; CLINICAL ARTICLE; CONTROLLED STUDY; DATA ANALYSIS; FEMALE; GLUCOSE METABOLISM; HUMAN; IMPAIRED GLUCOSE TOLERANCE; INSULIN RESISTANCE; MALE; ORAL GLUCOSE TOLERANCE TEST; PANCREAS ISLET BETA CELL; RETROSPECTIVE STUDY; STATISTICAL SIGNIFICANCE;

ADOLESCENT; ADULT; BETA-THALASSEMIA; CHELATION THERAPY; DEFEROXAMINE; DRUG THERAPY, COMBINATION; FEMALE; GLUCOSE TOLERANCE TEST; HUMANS; IRON CHELATING AGENTS; MALE; PYRIDONES; RETROSPECTIVE STUDIES;

EID: 33846897786     PISSN: 01688227     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.diabres.2006.07.010     Document Type: Article

References (25)

1. Italian working group on endocrine complications in non-endocrine diseases. Multicentre study on prevalence of endocrine complications in thalassemia major. Clin. Endocrinol. 42 (1995) 581-586
2. Khalifa A.S., Salem M., Mounir E., El-Tawil M.M., El-Sawy M., and Abd Al-Aziz M.M. Abnormal glucose tolerance in Egyptian beta-thalassemic patients: possible association with genotyping. Pediatr. Diab. 5 September (3) (2004) 126-132
3. Chern J.P., Lin K.H., Lu M.Y., Lin D.T., Lin K.S., Chen J.D., et al. Abnormal glucose tolerance in transfusion-dependent beta-thalassemic patients. Diab. Care 24 May (5) (2001) 850-854
4. Merkel P.A., Simonson D.C., Amiel S.A., Plewe G., Sherwin R.S., Pearson H.A., et al. Insulin resistance and hyperinsulinemia in patients with thalassemia major treated by hypertransfusion. N. Engl. J. Med. 318 March (13) (1988) 809-814
5. Cavallo-Perin P., Pacini G., Cerutti F., Bessone A., Condo C., Sacchetti L., et al. Insulin resistance and hyperinsulinemia in homozygous beta-thalassemia. Metabolism 44 March (3) (1995) 281-286
6. Monge L., Pinach S., Caramellino L., Bertero M.T., Dall'omo A., and Carta Q. The possible role of autoimmunity in the pathogenesis of diabetes in B-thalassemia major. Diab. Metab. 27 April (2 Pt. 1) (2001) 149-154
7. Borgna-Pignatti C., Rugolloto S., De Stefano P., Pica A., Di Gregorio F., Gamberini M.R., et al. Survival and disease complications in thalassemia major. Ann. NY Acad. Sci. 850 (1998) 227-231
8. Piga A., Gaglioti C., Fogliacco E., and Tricta F. Comparative effects of deferiprone and deferoxamine on survival and cardiac disease in patients with thalassemia major: a retrospective analysis. Haematologica 88 May (5) (2003) 489-496
9. Glickstein H., El R.B., Shvartsman M., and Cabantchik Z.I. Intracellular labile iron pools as direct targets of iron chelators: a fluorescence study of chelator action in living cells. Blood 106 November (9) (2005) 3242-3450
10. Kattamis A. Combined Therapy with Deferoxamine and Deferiprone. Ann. NY Acad. Sci. 1054 November (2005) 175-182
11. Origa R., Bina P., Agus A., Crobu G., Defraia E., Dessi C., et al. Combined therapy with deferiprone and desferrioxamine in thalassemia major. Haematologica 90 October (10) (2005) 1309-1314
12. Platis O., Anagnostopoulos G., Farmaki K., Posantzis M., Gotsis E., and Tolis G. Glucose metabolism disorders improvement in patients with thalassaemia major after 24-36 months of intensive chelation therapy. Pediatr. Endocrinol. Rev. Suppl. 2 (2004) 279-281
13. World Health Organization. Definition, Diagnosis and Classification of Diabetes Mellitus and its Complications (1999), World Health Organization, Geneva
14. Gutt M., Davis C.L., Spitzer S.B., Llabre M.M., Kumar M., Czarnecki E.M., et al. Validation of the insulin sensitivity index (ISI (0, 120)): comparison with other measures. Diab. Res. Clin. Pract. 47 March (3) (2000) 177-184
15. Matthews D.R., Hosker J.P., Rudenski A.S., Naylor B.A., Treacher D.F., and Turner R.C. Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 28 July (7) (1985) 412-419
16. Borgna-Pignatti C., Cappellini M.D., DE Stefano P., Del Vecchio G.C., Forni G.L., Gamberini M.R., et al. Survival and complications in thalassemia. Ann. NY Acad. Sci. 1054 November (2005) 40-47
17. Gamberini M.R., Fortini M., De Sanctis V., Gilli G., and Testa M.R. Diabetes mellitus and impaired glucose tolerance in thalassaemia major: incidence, prevalence, risk factors and survival in patients followed in the Ferrara Center. Pediatr. Endocrinol. Rev. Suppl. 2 (2004) 285-291
18. Messina M.F., Lombardo F., Meo A., Miceli M., Wasniewska M., Valenzise M., et al. Three-year prospective evaluation of glucose tolerance, beta-cell function and peripheral insulin sensitivity in non-diabetic patients with thalassemia major. J. Endocrinol. Invest. 25 June (6) (2002) 497-501
19. Link G., Konijn A.M., Breuer W., Cabantchik Z.I., and Hershko C. Exploring the "iron shuttle" hypothesis in chelation therapy: effects of combined deferoxamine and deferiprone treatment in hypertransfused rats with labeled iron stores and in iron-loaded rat heart cells in culture. J. Lab. Clin. Med. 138 August (2) (2001) 130-138
20. Giardina P.J., and Grady R.W. Chelation therapy in beta-thalassemia: an optimistic update. Semin. Hematol. 38 October (4) (2001) 360-366
21. Daar S., and Pathare A.V. Combined therapy with desferrioxamine and deferiprone in beta thalassemia major patients with transfusional iron overload. Ann. Hematol. February (1) (2006) 1-5
22. Mourad F.H., Hoffbrand A.V., Sheikh-Taha M., Koussa S., Khoriaty A.I., and Taher A. Comparison between desferrioxamine and combined therapy with desferrioxamine and deferiprone in iron overloaded thalassaemia patients. Br. J. Haematol. 121 April (1) (2003) 187-189
23. Gamberini M.R., Fortini M., Gilli G., Testa M.R., and De Sanctis V. Epidemiology and chelation therapy effects on glucose homeostasis in thalassaemic patients. J. Pediatr. Endocrinol. Metab. 11 Suppl. 3 (1998) 867-869
24. Labropoulou-Karatza C., Goritsas C., Fragopanagou H., Repandi M., Matsouka P., and Alexandrides T. High prevalence of diabetes mellitus among adult beta-thalassaemic patients with chronic hepatitis C. Eur. J. Gastroenterol. Hepatol. 11 September (9) (1999) 1033-1036
25. Mowla A., Karimi M., Afrasiabi A., and De Sanctis V. Prevalence of diabetes mellitus and impaired glucose tolerance in beta-thalassemia patients with and without hepatitis C virus infection. Pediatr. Endocrinol. Rev. Suppl. 2 (2004) 282-284